Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Denali Therapeutics

Tracked across 3 events · 35 articles · First seen Apr 03, 2026 · Last active Jul 14, 2026

Sentiment
40
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 30
Business
Impact: Denali Therapeutics regained full rights to DNL593 after Takeda terminated their collaboration, allowing Denali Therapeutics to independently advance the therapy for FTD-GRN.
Apr 03, 2026 · 7 articles
4 70
Business
Impact: Denali Therapeutics Inc. sold its Rare Pediatric Disease Priority Review Voucher for $195 million, which will strengthen its financial flexibility and fund the advancement of its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.
Jun 18, 2026 · 6 articles
6 20
Tech
Impact: Denali is developing transport vehicle technology to deliver Alzheimer's drugs across the blood-brain barrier, targeting tau and amyloid.
Jul 14, 2026 · 22 articles
ERGEN INTELLIGENCE
Track Denali Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.